Skip to content
Newcells Biotech
  • Our expertise
  • Our offerings
  • News & Blog
  • Collaborate
Newcells Biotech

News, Blog & Events

Newcells hiPSC lung models; Valuable tools in understanding health impacts of air pollution
read

News, Blog & Events

Newcells Biotech acquires IP for Retinal Organoids from Newcastle University
read

News, Blog & Events

Vision for the Future of Childhood Retinal Dystrophies
read

News, Blog & Events

Newcells Biotech Ltd. RPE Model to Improve Drug Retinal Toxicity Assessment
read

News, Blog & Events

Dr Frank Armstrong appointed as Non-executive Director
read

News, Blog & Events

iPSC derived retinal organoids: A Promising Tool for Modelling Retinitis Pigmentosa
read

News, Blog & Events

Newcells Biotech technology: the fight against antibacterial resistance
read

News, Blog & Events

Newcells Biotech Win Phase I of CRACK IT Challenge 29: ImmuLiver – Securing £99,711 Funding
read

News, Blog & Events

Looking Forward: A Year in Review
read

News, Blog & Events

Newcells Head to Boston
read
BY Newcells Biotech
November 11, 2019November 11, 2019
Blog

Newcells hiPSC lung models; Valuable tools in understanding health impacts of air pollution

In 2014, the World Health Organisation (WHO) estimated that air pollution leads to 7 million deaths per year. This figure is more than the number of deaths from AIDS, malaria and tuberculosis

Child retinal dystrophy
BY Newcells Biotech
September 2, 2019
Blog

Vision for the Future of Childhood Retinal Dystrophies

The retina is the means through which most people primarily perceive the world and for children particularly, visual defects can affect educational, social and emotional development.1 The importance of retinal disease, in

retinal pigmented epithelium (RPE)
BY Newcells Biotech
July 24, 2019
Blog

Newcells Biotech Ltd. RPE Model to Improve Drug Retinal Toxicity Assessment

Retinal toxicity is an adverse side effect that can cause (usually irreversible) deterioration of a person’s vision, when taking certain medication. This has been seen for example in people taking Hydroxychloroquine for Malaria due to toxicity to the retinal cells.  The retinal pigmented epithelium (RPE) is

BY Newcells Biotech
June 13, 2019
Blog

iPSC derived retinal organoids: A Promising Tool for Modelling Retinitis Pigmentosa

Retinitis pigmentosa (RP) is a group of degenerative disorders of the retina, caused by mutations in one of more than 60 genes, including the genes for making rhodopsin, pre-mRNA processing factors and usherin. The genes

Antibacterial resistance
BY Newcells Biotech
May 22, 2019
Blog

Newcells Biotech technology: the fight against antibacterial resistance

Antibacterial resistance is an ever-increasing concern for today’s society. As more bacterial strains become resistant to greater numbers of antibiotics, we could see modern-day healthcare rewind back to the mid-1940’s, when antibiotics

BY Newcells Biotech
December 20, 2018
Blog

Looking Forward: A Year in Review

2018 has been a significant year for Newcells Biotech. We have secured substantial investment, launched new, ground-breaking products, attended global events and expanded our every growing team.   Here are some of our defining moments

BY Newcells Biotech
November 9, 2018
Blog

ESTIV 2018 International Congress

Congress Round-Up The International Congress on in vitro Toxicology (ESTIV2018) organised by the European Society of Toxicology was held in Berlin this October 2018.  This year marks its 20th meeting, with the general theme of new approach methodologies

BY Newcells Biotech
September 17, 2018
Blog

Retinal Organoids: Mini Organs Add a New Dimension to our Understanding of the Eye

Retinal organoids are becoming a powerful tool in the process of drug discovery, as recently shown by researchers at Newcells Biotech and Newcastle University in a study led by Professor Majlinda Lako

BY Newcells Biotech
June 20, 2018June 20, 2018
Blog

Review Article – Cellular regeneration strategies for macular degeneration: past, present and future

Age-related macular degeneration (AMD) remains the commonest cause of blindness in the developed world. This review article by Dr Valeria Chichagova and Dr Dean Hallam provides an overview of progress made, ongoing studies and challenges ahead.

BY Dr Mike Nicholds
December 13, 2017May 22, 2018
Blog

Current cell-based screens are poor models of human biology

Current cell assays for in vitro screening are based on genetically modified cell lines which are crude models of human biology.

BY Dr Mike Nicholds
December 13, 2017May 22, 2018
Blog

hiPSCs derived cells in disease modelling

The discovery in 2007 that cells isolated from mature human tissues can be reprogrammed into cells that show pluripotency was a major breakthrough in stem cell science.

Sign-up to our newsletter for the latest information about our work and projects.

  • About Newcells Biotech
  • Management team
  • News, blog & events
  • Careers
  • Contact us
  • Privacy policy
  • Terms of use

The Core
Bath Lane
Newcastle Helix
Newcastle upon Tyne
NE4 5TF
UK
T: +44 (0) 333 344 6291
© Newcells Biotech Limited 2019
Newcells Biotech Limited is registered in England, company number: 09389592
Time Central, 32 Gallowgate, Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE1 4BF